참고문헌
- Anders CK, Carey LA (2009). Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clinical Breast Cancer, 9, 73-81. https://doi.org/10.3816/CBC.2009.s.008
- Andre F, Zielinski C (2012). Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncology, 23, 46-51. https://doi.org/10.1093/annonc/mdr047
- Aysola K, Desai A, Welch C, et al (2013). Triple negative breast cancer-an overview. Hereditary Genetics: Current Research, 2013.
- Berrada N, Delaloge S, Andre F (2010). Treatment of triplenegative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol, 21, 30-5. https://doi.org/10.1093/annonc/mdq279
- Bidard F-C, Matthieu M-C, Chollet P, et al (2008). p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol, 19, 1261-5. https://doi.org/10.1093/annonc/mdn039
- Burstein HJ, Harris JR, Morrow M (2008). Malignant tumors of the breast. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott, Williams & Wilkins, 1606-54.
- Edge SB, Byrd DR, Compton CC, et al (2010). AJCC cancer staging manual, Springer New York.
- Gerdes J, Li L, Schlueter C, et al (1991). Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol, 138, 867.
- Gluz O, Liedtke C, Gottschalk N, et al (2009). Triple-negative breast cancer-current status and future directions. Ann Oncol, 492.
- Inwald E, Klinkhammer-Schalke M, Hofstädter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients:results of a large population-based cohort of a cancer registry. Breast Cancer Res Treatment, 139, 539-52. https://doi.org/10.1007/s10549-013-2560-8
- Keam B, Im S-A, Lee K-H, et al (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 13, 22.
- Liedtke C, Mazouni C, Hess KR, et al (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26, 1275-81. https://doi.org/10.1200/JCO.2007.14.4147
- Liu M, Mo QG, Wei CY, et al (2013). Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis. Oncology letters, 5, 983-91. https://doi.org/10.3892/ol.2012.1093
- Luporsi E, Andre F, Spyratos F, et al (2012). Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treatment, 132, 895-915. https://doi.org/10.1007/s10549-011-1837-z
- Masuda H, Baggerly KA, Wang Y, et al (2013). Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. ASCO Annual Meeting Proc, 1005.
- Mayer IA, Abramson VG, Lehmann BD, et al (2014). New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clinical Cancer Res, 20, 782-90. https://doi.org/10.1158/1078-0432.CCR-13-0583
- Milde-Langosch K, Karn T, Muller V, et al (2013). Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treatment, 137, 57-67. https://doi.org/10.1007/s10549-012-2296-x
- Peddi PF, Ellis MJ, Ma C (2011). Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer, 2012.
- Rocca A, Viale G, Gelber RD, et al (2008). Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemotherapy Pharmacol, 61, 965-71. https://doi.org/10.1007/s00280-007-0551-3
- Silver DP, Richardson AL, Eklund AC, et al (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol, 28, 1145-53. https://doi.org/10.1200/JCO.2009.22.4725
- Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. https://doi.org/10.1073/pnas.191367098
- Von Minckwitz G, Martin M (2012). Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol, 23, 35-9.
- Yerushalmi R, Woods R, Ravdin PM, et al (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83. https://doi.org/10.1016/S1470-2045(09)70262-1
피인용 문헌
- The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis vol.13, pp.9, 2017, https://doi.org/10.2217/fon-2016-0420
- Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer vol.96, pp.51, 2017, https://doi.org/10.1097/MD.0000000000009384
- Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy pp.1573-7217, 2018, https://doi.org/10.1007/s10549-018-4985-6
- OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer vol.25, pp.4, 2018, https://doi.org/10.1007/s12282-018-0844-x